Indovazin-Teva gel 45 g — Made in Czech Republic — Free Delivery

Indovazin is a combined therapeutic agent, which includes indomethacin and troxerutin. indomethacin has a pronounced anti-inflammatory, analgesic and anti-edema effect. its use leads to the elimination of pain, a decrease in edema and a reduction in the time of functional rehabilitation in case of damage to joints and tissues. the mechanism of action is associated with inhibition of the synthesis of prostaglandins by reversible blockade of cog. indomethacin has a more pronounced anti-inflammatory effect compared to salicylates and phenylbutazone.

Troxerutin (trihydroxyethylrutinoside) is a bioflavonoid. It belongs to angioprotective agents. Troxerutin reduces capillary permeability and exhibits a venotonic effect. Blocks the venodilating effect of histamine, bradykinin and acetylcholine. It has an anti-inflammatory effect on the peri-venous tissue, reduces capillary fragility and exhibits a certain antiplatelet effect. Reduces edema, improves trophism in pathological changes associated with venous insufficiency.

When applied to the skin, Indovazin inhibits the reactions of inflammation and edema, eliminates pain and temperature in the foci of inflammation (outside and in deep tissues, reaching the blood vessels). Shows venotonic, capillary-protective and hemostatic action.

The gel base of the preparation contributes to the complete solubility of the active ingredients and their maximum release. The dosage form in the form of a gel, which includes indomethacin and troxerutin, provides good absorption from the skin surface and therapeutic effect at different levels, creating the necessary concentrations in inflamed tissues and synovial fluid.

Indomethacin binds to plasma proteins by more than 90% and lends itself to intensive biotransformation in the liver by O-demethylation and N-deacetylation to inactive compounds.

Troxerutin is a mixture of hydroxyethyl derivatives of the bioflavonoid rutin (O- (B-hydroxyethyl) rutosides), in which trihydroxyethylrutoside (troxerutin) predominates.

Indomethacin is excreted in urine (60%), bile and feces (30%). Penetrates into breast milk, and therefore it is not recommended to use Indovazin during breastfeeding.

Most of the resorbed tri-, di- and monohydroxyethylrutosides are excreted in the bile, a much smaller part - by the kidneys. Tetrahydroxyethylrutoside is excreted mainly in the urine.

Bruises, sprains, dislocations, hematomas, edema, myositis, neuralgia, lumbago, sciatica, sciatica, osteochondrosis, arthritis, joint pain.

It is applied externally: 4–5 cm of gel is applied 3-4 times a day in a thin layer on the affected areas with light massaging movements. the total daily dose should not exceed 20 cm. The duration of treatment is no more than 10 days.

Hypersensitivity to the components of the preparation; hypersensitivity to NSAIDs.

In isolated cases, there are reactions of skin irritation in the form of hyperemia, itching, skin rashes, which quickly disappear after the preparation is discontinued.

It is not recommended to use indomethacin in children under 14 years of age, due to the lack of sufficient clinical experience.

It is not recommended to prescribe the preparation to patients with a history of indications or proven hypersensitivity to food and medicines; in the presence of asthma, allergic rhinitis or other allergies.

Indovazin is applied only to intact skin. It is necessary to avoid contact of the gel on mucous membranes, open surfaces of wounds and eyes.

If the duration of treatment is more than 10 days, it is necessary to conduct laboratory control of the leukocyte and platelet blood count.

The preparation contains sodium benzoate and propylene glycol, which can cause skin irritation.

Given that there is no clinical experience that proves the safety of using Indovazin during pregnancy and lactation, the use of the preparation is possible only in cases where the benefits of its use outweigh the potential risk.

The preparation should not be used in conjunction with other NSAIDs (potentiation of the effect) and corticosteroids (possible potentiation of their ulcerogenic action).